Navigation Links
Clermont Pharmaceuticals Reports Positive Phase III Results for Drug to Treat Glaucoma

TAMPA, Fla., Sept. 26, 2011 /PRNewswire/ -- Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost In the study, non-preserved latanoprost was compared to Xalatan® (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.  Non-preserved latanoprost achieved the primary efficacy endpoint of non-inferiority to Xalatan.  In addition, non-preserved latanoprost was better tolerated than Xalatan, with statistically fewer ocular symptoms on instillation and significantly fewer subjects with conjunctival hyperemia.  Xalatan is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension; it was approved by the US Food and Drug Administration for use in 1996.  Xalatan is the registered trademark of Pfizer, Inc. 

Clermont obtained the US rights to non-preserved latanoprost from Laboratoires Thea S.A.S, an ophthalmic pharmaceutical company based in France.  Laboratoires Thea recently filed an application for European marketing authorization with the EMEA. 

Based on these positive results, Clermont intends to file a New Drug Application with the US FDA in the fourth quarter of 2011.  Clermont plans to begin discussions with potential marketing partners in the near future.   

About Open-Angle Glaucoma

Open-angle glaucoma is the most common type of glaucoma and the leading cause of blindness among adults in the US – mostly because it can progress gradually and go unnoticed for years.  An increase in eye pressure occurs slowly over time.  This pressure pushes on the optic nerve and the retina at the back of the eye.  The cause of open-angle glaucoma is unknown, but it tends to be hereditary, with people of African descent at particularly high risk. 

About Clermont Pharmaceuticals

Clermont Pharmaceuticals, Inc. is a privately held Florida based ophthalmic pharmaceutical company focused on the development of new medicines for the treatment glaucoma. 

About Laboratoires Thea

Laboratoires Thea was founded in 1994 and is managed by Henri and Jean-Frederic Chibret. Laboratoires Thea is a 350 MUSD ophthalmic pharmaceutical company and is the leading independent ophthalmic group in Europe and is committed to the development and marketing of innovative ophthalmic drugs, medical devices, and nutraceuticals.

SOURCE Clermont Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
2. Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
3. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
4. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
5. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
6. Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
7. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
8. Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
9. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
10. Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing
11. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 As enforcement of ... Chain Security Act (DSCSA) approaches, InfiniTrak ... independent pharmacies comply with looming FDA regulations. ... is entering endorsement agreements with State Pharmacy Associations, ... administration organization (PSAO) to exclusively provide the InfiniTrak ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 /PRNewswire/ ... announced the addition of the "Spinal ... Growth, Trends, and Forecast 2015 - 2023" ... ) has announced the addition ... - Pipeline Assessment, Size, Growth, Trends, and ...
(Date:12/1/2015)... -- Royal Philips  (NYSE: PHG, AEX: ... software that produces high-contrast images for all anatomies in ... at the 2015 Radiological Society of North America ... first digital imaging solution providing grid-like contrast improvement and ... and supports "first-time-right imaging" by decreasing the need for ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... Royal River Natural Foods — a locally-owned, independent natural health store in ... nutritional supplement creatine, along with resistance training for a year, had more new bone ... report is part of the December 2015 issue of Natural Insights for Well Being®, ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article ... filed a discrimination claim against the U.S. Department of Health and Human Services, claiming ... Act (ACA) plans are breaking the clause in the law prohibiting the denial of ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one of ... iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design Awards, ... that it has been selected as a 2015 U.S.A. Taste Champion in the American ...
(Date:12/1/2015)... ... ... Growth in medical payments per workers’ compensation claim in Louisiana slowed from ... care, according to a recent study by the Workers Compensation Research Institute (WCRI). ... payments per claim with more than seven days of lost time continued to be ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS ... 2015 Golden Bridge Business Awards under the New Products and Services category for ... based sample management software that helps labs organize data and track ...
Breaking Medicine News(10 mins):